top of page
  • Completed

NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for RRMM

Updated: Apr 26, 2022

NCT02215967: Phase 1 - Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma


nci bcma cart

Background: - T cells are white blood cells that fight several cancers. One cancer therapy involves removing a persons' T cells, changing them in a lab, and then returning them to the person. Researchers want to see if this helps people with multiple myeloma.


Objective: - To test the safety of giving anti-B-Cell Maturation Antigen T cells to people with multiple myeloma.


Sponsor: National Cancer Institute (NCI)


ClinicalTrials.gov Identifier: NCT02215967


Official Title: A Phase I Clinical Trial of T-Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma


Click here for details on Clinicaltrials.gov

 

CART - BCMA : National Cancer Institute

 

Drug: Cyclophosphamide

Drug: Fludarabine

Biological: Anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cells

 

J Clin Oncol; 2018 Aug

T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma

https://pubmed.ncbi.nlm.nih.gov/29812997/





Posts Archive
bottom of page